Eclipsebio acquired Terrain Bio to combine Terrain’s machine‑learning RNA analytics with Eclipsebio’s sequencing‑first RNA characterization, aiming to build an end‑to‑end RNA design, manufacturing and validation platform. Eclipsebio said the deal will let it support RNA drug developers earlier in design and provide high‑resolution assays for manufacturing robustness and quality‑by‑design. CEO Peter Chu framed the move as accelerating Eclipsebio’s vision to offer iterative design and deep sequencing validation for RNA therapeutics. Financial terms were not disclosed. The acquisition consolidates AI‑assisted design with analytics, an integration many RNA developers see as critical to reduce development cycle times.